echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Co-Creating a Star Program Zhiqiheal Future Colorectal Cancer Special Conference Academic Highlights Report

    Co-Creating a Star Program Zhiqiheal Future Colorectal Cancer Special Conference Academic Highlights Report

    • Last Update: 2021-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Abstract On the golden occasion of September, the curtain of "Recovering Energy, Star Ecology-The 2nd FOCUS SUMMIT" is unveiled again
    .

    The colorectal cancer session invited Professor Cai Sanjun, Chairman of Colorectal Cancer Center of Fudan University, Professor of Colorectal Surgery of Fudan University Cancer Hospital, Director of Zhejiang University Cancer Institute, and Professor Zhang Suzhan, Director of Cancer Center of the Second Affiliated Hospital of Zhejiang University School of Medicine, as the chair of the conference , And work with more than 30 authoritative experts in the field of colorectal cancer to discuss new standards and new patterns of colorectal cancer treatment
    .

    This platform hereby sorts out the highlights of the conference and shares the progress with readers
    .

    Big coffee gathered to start the colorectal cancer special session with the welcome speech of Professor Chen Luning, co-president of Jiangsu Fosun Pharma
    .

    He said that Fosun Pharma is still a newcomer in the field of oncology, and will continue to devote itself to the development of solid tumor treatment in the future to promote the development of China's health industry
    .

    Chairpersons of the conference, Professor Cai Sanjun and Professor Zhang Suzhan delivered opening speeches
    .

    The two professors said that in recent years, the incidence of colorectal cancer in China has continued to rise.
    Although the 5-year survival has improved significantly, there is still a gap according to the international advanced level.
    It is still necessary for all colleagues to work together to advance the standardized prevention and treatment of colorectal cancer.
    Hope here In the meeting, the wisdom of experts was gathered to promote the diagnosis and treatment of bowel cancer to start a new journey
    .

    Session 1 guides and standardizes bowel movements.
    Session 1 is based on authoritative guidelines to discuss standardized diagnosis and treatment of colorectal cancer.
    Professor Zeng Shan from Ya Hospital and Professor Xiong Jianping from the First Affiliated Hospital of Nanchang University served as the chairpersons of this chapter
    .

    From top to bottom, from left to right: Professor Yuan Xianglin, Professor Gu Kangsheng, Professor Zeng Shan, Professor Xiong Jianping 2021 CSCO Colorectal Cancer Guidelines Update As a pocket book for colorectal cancer doctors, "CSCO Colorectal Cancer Diagnosis and Treatment Guidelines" covers The guidelines include general principles, MDT principles, screening and genetics, imaging and pathological diagnosis, and treatment principles for non-metastatic/metastatic colon cancer and rectal cancer
    .

    Professor Chen Gong from Sun Yat-sen University Cancer Center will interpret these five parts of the updated content in 2021.
    Among them, the principles of treatment of non-metastatic/metastatic colon cancer and rectal cancer are the focus of the guideline's annual update.
    Professor Chen Gong also combines his clinical practice The experience was analyzed
    .

    Non-metastatic colorectal cancer: 1) Based on the final OS results of the IDEA study, the CapeOX regimen adjuvant chemotherapy is preferred for patients with stage III colorectal cancer; 2) For unresectable colon cancer, according to the results of KEYNOTE 177, NICHE, FOxTROT, etc.
    , MSI -H/dMMR patients may consider using PD-1 inhibitors for immunotherapy in conversion therapy or palliative treatment
    .

    Metastatic colorectal cancer: 1) Based on the results of the KEYNOTE 177 study, it focuses on updating the immunotherapy and combination treatment recommendations for different groups of potentially resectable, initial unresectable, and palliative care; 2) When the metastasis is unresectable, for asymptomatic Whether to remove the primary tumor or not, it is emphasized that doctors need to evaluate carefully and make individualized decisions for each case
    .

    In terms of rectal cancer, it mainly focuses on patients who are technically difficult to preserve the anus but have a strong desire to preserve the anus.
    Considering the situation of the patient, a higher-intensity treatment plan/mode can be given before and during the perioperative period
    .

    Professor Chen Gong finally emphasized that the previous era when a model is applicable to all patients has passed.
    With the beginning of the era of precision treatment and individualized treatment, doctors need to keep learning and thinking to bring patients more suitable treatment plans
    .

    Viewing the new pattern of mCRC treatment from the JSCCR guidelines, Professor Qiu Meng, West China Hospital of Sichuan University, analyzes the new pattern of metastatic colorectal cancer (mCRC) treatment based on the JSCCR guidelines
    .

    Professor Qiu mainly discussed the recommendation and basis of the JSCCR guidelines for the third-line treatment of mCRC and the deployment of the third-line treatment of mCRC based on real-world research
    .

    She pointed out that Langsfer® (Trifluridine tepipyrimidine tablets) and TKIs are both the first-level recommended schemes of the JSCCR guidelines.
    A number of real-world studies (RWS) have shown that 54% to 75% of later-line patients use Langes first.
    Sever®
    .

    Moreover, the large sample of Japan RWS reminded that when both Lancefir® and Regofinil are available, Lancefir® will be given priority
    .

    For patients with hand-foot skin reactions or hand-foot syndrome, the third-line treatment is preferred to choose Lancefre®, and TKIs should be used with caution to avoid aggravation or recurrence of hand-foot skin reactions
    .

    Adverse events related to bone marrow function caused by front-line treatment can be recovered, and it does not affect the choice of third-line treatment
    .

    Wonderful discussion Professor Yin Fei from the Fourth Hospital of Hebei Medical University, Professor Wan Yiye from Jiangxi Cancer Hospital, Professor Bi Qing from Yunnan Cancer Hospital, Professor Lv Yingqian from the Second Affiliated Hospital of Hebei Medical University, Professor Tan Shisheng from Guizhou Provincial People's Hospital as the panelists, combined Cases of advanced bowel cancer are discussed
    .

    They pointed out that the treatment of colon cancer not only pursues long-term survival, but also pays attention to the quality of life of patients
    .

    According to clinical practice, Lancefre® brings more choices to patients, and the clinical application has satisfactory efficacy and controllable adverse reactions
    .

    In addition, the immunotherapy and targeted therapy of colorectal cancer have made abundant progress, and there are still many areas worth exploring in the diagnosis and treatment of colorectal cancer in the future
    .

    Session 2 is based on high-level evidence-based medicine.
    Session 2 discusses the new treatment standards and treatment pattern of metastatic colorectal cancer from the perspectives of clinical exploration and clinical practice.
    This session is sponsored by the Sichuan Cancer Hospital.
    Professor Jin, Professor Li Enxiao from the First Affiliated Hospital of Xi'an Jiaotong University, Professor Cai Xiaohong from Sichuan Cancer Hospital, and Professor Li Shengmian from the Fourth Hospital of Hebei Medical University served as the chairpersons of the meeting
    .

    From top to bottom, from left to right: Professor Yan Jin, Professor Li Enxiao, Professor Cai Xiaohong, Professor Li Shengmian From clinical exploration to guideline recommendation-the new standard for the treatment of metastatic colorectal cancer The majority of patients with stage IV colorectal cancer in China, 5 The annual OS rate is lower than Europe, America and Japan
    .

    Professor Liu Hongli from the Union Hospital of Tongji Medical College of Huazhong University of Science and Technology discussed the exploration and new standards of the posterior treatment of mCRC based on basic research, clinical research, NCCN guidelines and CSCO guidelines
    .

    Professor Liu pointed out that chemotherapy is the cornerstone of systemic treatment of mCRC, and front-line chemotherapy combined with targeted therapy can bring sustained survival benefits to patients
    .

    The physical status of third-line patients is not inferior to that of front-line patients, and they are allowed to receive active treatment
    .

    As a new option for mCRC chemotherapy, Lancefre® brings new opportunities for combined targeted therapy
    .

    From the perspective of clinical practice, treatment options-the new pattern of third-line treatment for metastatic colorectal cancer.
    Chinese mCRC patients are increasing year by year, and the 5-year survival rate is increasing year by year.
    This is closely related to the increasingly standardized first- and second-line treatment of mCRC in China, but the third-line treatment plan still needs to be standardized
    .

    Professor Wang Chang from the First Hospital of Jilin University elaborated on the status quo of mCRC third-line treatment, standard treatment options, and real-world inspiration
    .

    Professor Wang pointed out that in recent years, the rate of third-line treatment for mCRC in China has increased.
    >80% of patients have no targets for intervention and cannot receive precision treatment.
    The guidelines recommend standard third-line treatment options for trifluridine and anti-VEGF TKIs
    .

    Based on RCT, patients ≥65 years old have more obvious benefits from Lancefre® treatment; for patients with HSFR/HSF, Lancefre® is the preferred third-line treatment
    .

    RWS in the United States showed that the treatment compliance of Lancefer® was significantly higher than that of regorafenib, and patients who used Lancefer® first and then regorafenib had higher compliance and durability, which could bring better survival benefits ; The large sample of RWS in Japan shows that compared with regorafenib single drug, Lancefol® single-drug prolongs mOS significantly, and has a lower incidence of adverse reactions and longer duration of treatment; when both drugs are available, it is best to first Give Lancefre® treatment
    .

    Exciting discussion and discussion sessions were conducted by Professor Cheng Yong from the First Affiliated Hospital of Chongqing Medical University, Professor Bai Wei from Shanxi Cancer Hospital, Professor He Yifu from Anhui Cancer Hospital, Professor Zhang Congjun from the First Affiliated Hospital of Anhui Medical University, and Professor Wang Feng from the First Affiliated Hospital of Zhengzhou University Discuss the clinical efficacy and safety of Lancefre®, as well as the exploration of joint programs.
    It is expected that there will be more safe and effective treatment options for the late-line treatment of patients with advanced bowel cancer
    .

    Session 3 cases of real knowledge, optimized escort Session 3 is based on clinical cases of colorectal cancer treatment, discusses the clinical management of colorectal cancer, by Professor Luo Suxia from Henan Cancer Hospital, Professor Zang Aimin, Affiliated Hospital of Hebei University, Professor Li Yongsheng, Affiliated Cancer Hospital of Chongqing University , Professor Chen Xiaobing from Henan Cancer Hospital served as the chair of the meeting
    .

    From top to bottom, from left to right: Professor Luo Suxia, Professor Zang Aimin, Professor Li Yongsheng, Professor Chen Xiaobing Case report on advanced rectal cancer Advanced cases with malignant tumors were shared.
    The genetic test of the patients showed KRAS Exon2 G12S/G12D mutation, NRAS wild-type, BRAF wild-type; immunohistochemistry was HER2 negative, pMMR
    .

    The patient was treated with Fruquintinib during the initial third-line treatment.
    Due to side effects, he was switched to TAS-102 treatment.
    SD was 2 months.
    After the review progressed, he used TAS-102+bevacizumab for 2 cycles; during the treatment period , The safety is good, the patient can tolerate, the best supportive treatment after PD, the patient's total OS is 32 months
    .

    The management of thrombocytopenia caused by anti-tumor treatment of colorectal cancer Chemotherapy can lead to the occurrence of thrombocytopenia (TCP).
    Professor Ji Chushu from the First Affiliated Hospital of University of Science and Technology of China explained the anti-tumor of colorectal cancer from the mechanism, clinical harm and treatment methods.
    Management of thrombocytopenia caused by treatment
    .

    Professor Ji pointed out that oxaliplatin-containing chemotherapy is one of the main causes of thrombocytopenia in patients with colorectal cancer
    .

    Thrombocytopenia will increase the risk of bleeding in patients with colorectal cancer, affect the dose and progress of chemotherapy, thereby reducing the survival rate of patients, and increase the medical expenses of patients with colorectal cancer
    .

    In the current treatment, platelet transfusion has risks such as exogenous infection and immune response.
    The adverse reaction rate of rhTPO and IL-11 infusion is high, and the safety is worthy of attention
    .

    Fortunately, in the 2019 CIT Expert Diagnosis and Treatment Consensus, oral TPO-RA has entered the consensus recommendation as a new treatment for the first time.
    Most experts believe that patients who do not respond well to IL-11 and or TPO can be considered for use
    .

    Avatrippapar is currently approved for CLD-related thrombocytopenia in China, FDA approved for primary immune thrombocytopenia, and CIT Phase III global clinical studies are ongoing
    .

    At present, retrospective studies have initially confirmed its effectiveness in the treatment of CIT, and its safety is good; we look forward to the publication of its clinical results, so that patients can use more effective, safer and more convenient prevention and treatment methods and measures
    .

    Wonderful discussion guests Professor Sun Hao from Chongqing Cancer Hospital, Professor Shi Jian from the Fourth Hospital of Hebei Medical University, Professor Suo Aili from the First Affiliated Hospital of Xi'an Jiaotong University, Professor Sui Hong from Heilongjiang Cancer Hospital, Professor Chen Kehe from the People's Hospital of Guangxi Zhuang Autonomous Region Discussed the precise and standardized treatment of bowel cancer from the perspective of medicine and surgery.
    It is believed that the safety and tolerability of drug therapy is very important for the treatment of elderly patients.
    TAS-102 enriches the treatment options for advanced bowel cancer and can bring more to patients.
    Multiple treatment options; while emphasizing the prevention and standardized diagnosis and treatment of patients with thrombocytopenia, oral TPO-RA avatropopag brings more options for patients who are unwilling to receive frequent subcutaneous injections, and has been recommended by expert consensus
    .

    According to legend, the bowel treatment and long-term safety conference came to an end in a heated discussion.
    The chairmen of the conference, Professor Cai Sanjun and Professor Zhang Suzhan, delivered concluding speeches
    .

    They said with satisfaction that they saw the growth of the young and middle-aged doctors in this conference, which can be expected to become the mainstay in the field of cancer treatment.
    At the same time, the two professors fully affirmed the academic content of this conference and congratulated the conference for its complete success
    .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.